Prozac Articles
LILLY'S PROZAC AND OBSESSIVE-COMPULSIVE DISORDER
22 November 1993
EUROPE'S NEW COST-CONSCIOUS ENVIRONMENT
8 November 1993
OCD PATIENTS RESPOND TO FLUVOXAMINE
1 November 1993
LILLY APPOINTMENTS
25 October 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
FURTHER INDICATION FOR LILLY'S PROZAC?
26 July 1993
ELI LILLY CHIEF IN RESIGNATION ROW
5 July 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
ANTIDEPRESSANTS AND MISCARRIAGE
24 May 1993
SB AND J&J TO COPROMOTE IN USA
24 May 1993
FDA PANEL BACKS EFFEXOR
10 May 1993
HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS
3 May 1993
US 1st QTRs IN LINE WITH EARLIER WARNINGS
26 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
ELI LILLY ISSUES 1st QTR WARNING
22 March 1993
DOUBLE TROUBLE FOR SMITHKLINE BEECHAM
22 March 1993
SIDE EFFECTS WITH PAROXETINE?
15 March 1993
NEW MAOIs: NOT SELECTIVE ENOUGH
8 March 1993
SB BEECHAM RESULTS; EXPLOITS STRENGTHS
1 March 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
FDA YEAR-END DRUG APPROVALS ROLL-OUT
4 January 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
DISTA LAUNCHES PROZAC LIQUID IN UK
4 January 1993
LILLY'S PLAN FOR PROZAC IN CANADA
21 December 1992
JOB CUTS AT BRISTOL-MYERS SQUIBB
9 November 1992
US RESULTS 3RD QTR
2 November 1992
FDA PANEL BACKS PAROXETINE APPROVAL
12 October 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
PROZAC APPROVED FOR OCD
5 October 1992
DATABASE AFFIRMS THE SAFETY OF FLUVOXAMINE
6 July 1992
Medicine secrecy in the UK
22 June 1992
ANALYSTS' CNS DRUGS COMMENTARY; USA
8 June 1992
TREATING DIABETIC NEUROPATHY
18 May 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
DEPRESSION: THE COST TO SOCIETY
6 April 1992
STOCK MARKET COMMENTARY: NEW YORK
16 March 1992
BULLETIN REVIEWS LILLY'S PROZAC
27 January 1992
YEAR-END FDA APPROVALS
6 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
